FDA advisory panel to consider approving fourth COVID-19 vaccine, this one from Maryland's Novavax
USA TodayDec 28, 2021
The Facts
On Wed., the Food and Drug Administration (FDA) approved emergency use authorization for Novavax's COVID vaccine. The approval provides a fourth vaccine option for American adults who have not yet received their first dose of any other vaccine.
Novavax's vaccine uses a protein-based formula while the Pfizer BioNTech and Moderna vaccines are both mRNA-based.
The Spin
Narrative A
Vaccine conspiracy theories tragically stigmatized mRNA jabs for millions of people in America. An "old school" protein-based jab, similar to the flu shot, could have more appeal to the unvaccinated. US officials bet the farm on mRNA products, and it's wise to offer consumers alternatives.
Narrative B
Novavax is a latecomer to the COVID vaccine landscape, and its early production fumbles were costly. The market is already well established by Pfizer and Moderna in the US, and whether its non-mRNA formula will be accepted by entrenched vaccine skeptics remains very much to be seen.
Metaculus Prediction
Articles on this story
Sign Up for Our Free NewslettersSign Up for Our Free Newsletters
Sign Up!
Sign Up Now!